Mixed trend on the daily chart: above its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Jun 26 · below the Ichimoku cloud · RSI 39 · MACD above its signal · at its 52-week low
| 0.0401 | 52-week high | +40000.00% |
| 0.000100 | Price now | |
| 0.000100 | R3 (classic) | −0.00% |
| 0.000100 | R2 (classic) | −0.00% |
| 0.000100 | R1 (classic) | −0.00% |
| 0.000100 | Pivot | −0.00% |
| 0.000100 | S1 (classic) | −0.00% |
| 0.000100 | S2 (classic) | −0.00% |
| 0.000100 | S3 (classic) | −0.00% |
| 0.000100 | Previous day high | −0.00% |
| 0.000100 | Previous day low | −0.00% |
| 0.000100 | Previous week high | −0.00% |
| 0.000100 | Previous week low | −0.00% |
| 0.000100 | Previous month high | −0.00% |
| 0.000100 | Previous month low | −0.00% |
| 0.000100 | 52-week low | −0.00% |
None of the 29 investors followed here reported a position in GBIM in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a GBIM trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for GBIM.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0% | ||
| 2025 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -50.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −50.0% |
| 2024 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0% |
| 2023 | 0.0 | 0.0 | 14.3 | 0.0 | -12.5 | -71.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −71.4% |
| 2022 | 49900.0 | 0.0 | -99.0 | 0.0 | 0.0 | 20.0 | 16.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | +600.0% |
| 2021 | 81.0 | 707.9 | -41.0 | -26.5 | 2.3 | -25.0 | -50.0 | -30.0 | -2.0 | 0.0 | -96.5 | -99.2 | −100.0% |
| 2020 | -3.6 | -4.9 | -9.1 | 11.4 | -2.6 | 10.5 | 346.4 | -20.0 | -50.0 | 12.0 | -12.5 | 42.9 | +150.0% |
| 2019 | -22.4 | 28.6 | -17.8 | -12.2 | -6.5 | 7.5 | -2.1 | -37.4 | 24.8 | -32.8 | 19.1 | 5.1 | −53.4% |
| 2018 | 45.5 | 25.6 | -9.4 | -39.0 | 8.3 | 44.7 | -2.7 | -12.1 | -48.9 | -11.7 | -10.4 | -5.0 | −48.1% |
| 2017 | 10.7 | -40.8 | 100.0 | -34.2 | 50.9 | 35.2 | -3.9 | 12.2 | -9.1 | 51.3 | -40.5 | -22.8 | +19.8% |
| 2016 | -22.2 | -65.8 | 102.9 | -7.5 | -38.4 | 63.0 | -56.7 | -6.9 | 59.8 | 4.0 | -53.8 | -51.7 | −92.5% |
| 2015 | -12.3 | 13.5 | -2.9 | -1.8 | -44.7 | -34.6 | -15.7 | 27.7 | -7.1 | -5.0 | 37.9 | 13.2 | −49.0% |
| 2014 | 14.6 | -34.9 | -18.5 | 16.3 | 15.9 | −18.1% |
TimeframesMixed on the hourly, daily, weekly and monthly.
under a flat 21 EMA
pulling back under the 21 EMA
pulling back under the 21 EMA
pulling back under the 21 EMA
No analyst coverage for this instrument.
GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platforms. The company's product candidate includes GS-4774, which is in Phase 2 trials for the treatment of patients with chronically infected with hepatitis B virus, as well as with oral antiviral suppressive therapy. The company is also involved in developing GI-6301 for the treatment of cancers expressing the brachyury protein; and GI-6207 that is in Phase 2 clinical trials to treat medullary thyroid cancer. In addition, it is involved in developing GI-4000, which is in Phase 2b clinical trials for the treatment of resected pancreas cancer; and is in Phase 2 clinical trial to treat non-small cell lung cancer, as well as is in Phase 2 clinical trial for the treatment of colorectal cancer. Further, the company is involved in developing various other product candidates targeting various infectious diseases that are in preclinical development stage, which include GI-19000 to treat tuberculosis; GI-2010 for the treatment of human immunodeficiency virus; and GI-18000 for hepatitis D virus infection. It has strategic collaborations with Gilead Sciences, Inc. and Celgene Corporation. The company was formerly known as Ceres Pharmaceuticals, Inc. and changed its name to GlobeImmune, Inc. in May 2001. GlobeImmune, Inc. was founded in 1995 and is headquartered in Louisville, Colorado. GlobeImmune, Inc. operates as a subsidiary of NantCell, Inc.
No recent headlines.